Walleye Capital LLC bought a new stake in Inhibrx, Inc. (NASDAQ:INBX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 579,999 shares of the company's stock, valued at approximately $8,932,000. Walleye Capital LLC owned approximately 4.01% of Inhibrx as of its most recent SEC filing.
Other institutional investors and hedge funds have also modified their holdings of the company. Barclays PLC acquired a new position in Inhibrx in the 4th quarter valued at approximately $289,000. Kennedy Capital Management LLC acquired a new stake in Inhibrx during the fourth quarter valued at $2,551,000. Arbiter Partners Capital Management LLC purchased a new position in Inhibrx in the fourth quarter valued at about $433,000. Yakira Capital Management Inc. acquired a new position in Inhibrx in the 4th quarter worth about $557,000. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Inhibrx during the 4th quarter valued at about $837,000. Hedge funds and other institutional investors own 82.46% of the company's stock.
Inhibrx Stock Down 0.7 %
Shares of Inhibrx stock traded down $0.08 during midday trading on Monday, reaching $11.40. 62,637 shares of the company's stock traded hands, compared to its average volume of 201,747. Inhibrx, Inc. has a 52 week low of $10.80 and a 52 week high of $34.75. The company's 50 day simple moving average is $13.13 and its 200 day simple moving average is $14.18.
Inhibrx (NASDAQ:INBX - Get Free Report) last announced its quarterly earnings results on Monday, March 17th. The company reported ($3.09) earnings per share for the quarter, missing analysts' consensus estimates of ($2.88) by ($0.21). The business had revenue of $0.10 million during the quarter. Sell-side analysts forecast that Inhibrx, Inc. will post 104.88 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Separately, JMP Securities restated a "market perform" rating on shares of Inhibrx in a report on Wednesday, January 22nd.
Get Our Latest Research Report on INBX
About Inhibrx
(
Free Report)
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Featured Stories
Before you consider Inhibrx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibrx wasn't on the list.
While Inhibrx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
